Shionogi to Release New Data at 2018 European Congress of Clinical Microbiology and Infectious Diseases

• Published in: Health & Beauty Close - Up
• Format: Newsletter
• Language: English
• Published: Jacksonville Close-Up Media, Inc 23.04.2018
• Subjects: Drug interactions; Infections; Infectious diseases; Influenza; Monoclonal antibodies; Pharmacodynamics; Pharmacokinetics; Proteins; Virulence; Spain

According to a media release, Shionogi will present at this congress data on three investigational compounds including cefiderocol (S-649266), an investigational siderophore cephalosporin with a novel mechanism of cell entry in late stage development with activity against a broad range of Gram-negative pathogens including multidrug resistant (MDR) strains; baloxavir marboxil (S-033188), an oral cap-dependent endonuclease inhibitor administered as a single dose for the treatment of influenza; and for the first time, COT-143, an investigational humanized monoclonal antibody demonstrating anti-virulence activity targeting the PcrV protein, an essential component of the Pseudomonas aeruginosa type III secretion system. The following cefiderocol presentations will take place during a cefiderocol-focused poster session on Saturday, April 21, from 15:30-16:30, in the paper poster arena: -Poster #P0184: Cefiderocol, a novel siderophore cephalosporin: in vitro activity against Stenotrophomonas maltophillia isolated globally Presenter: Masakatsu Tsuji -Poster #P0185: Stability of cefiderocol against clinically-significant broad-spectrum oxacillinases Presenter: Patrice Nordmann -Poster #P0186: Correlations between cefiderocol broth microdilution MICs and disk diffusion inhibitory zone diameters among target Gram-negative organisms Presenter: Masakatsu Tsuji -Poster #P0187: In vitro activity of cefiderocol (S-649266), a siderophore cephalosporin, against carbapenem-susceptible and resistant non-fermenting Gram-negative bacteria Presenter: Robert A. Bonomo -Poster #P0188: Metabolism and excretion of [14C]-cefiderocol, a siderophore cephalosporin, and drug-drug interaction potential via transporters of cefiderocol in healthy subjects Presenter: Miyazaki Shiro -Poster #P0189: In vivo pharmacokinetic/pharmacodynamic (PK/PD) assessment of cefiderocol against Stenotrophomonas maltophilia in a neutropenic murine lung infection model Presenter: Miki Takemura -Poster #P0190: Efficacy of humanized cefiderocol exposure against Stenotrophomonas maltophilia in a rat respiratory tract infection model Presenter: Miki Takemura -Poster #P0191: Stability and low induction potential of cefiderocol against chromosomal AmpC beta-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae Presenter: Miki Takemura The details for the baloxavir marboxil presentations are as follows: -Oral presentation #O0469: Lack of pharmacokinetic drug-drug interaction between baloxavir marboxil, a novel inhibitor of influenza virus cap-dependent endonuclease, and oseltamivir Presenter: Nao Kawaguchi Date and time: New aspects of antiviral therapies, paper poster arena The following COT-143 presentations will take place Tuesday, April 24, from 12:30-13:30, in the paper poster arena: -Poster #P2456: Correlation between production of PcrV protein in vitro/in vivo of clinical isolates of Pseudomonas aeruginosa and their virulence in a murine infection model Presenter: Hideki Maki -Poster #P2457: COT-143, a novel monoclonal antibody against the PcrV protein: in vivo efficacy and pharmacokinetic/pharmacodynamic assessment against Pseudomonas aeruginosa in murine lung infection models Presenter: Hideki Maki -Poster #P2458: COT-143, a novel monoclonal antibody against the PcrV protein: binding affinity against PcrV and in vitro cytotoxicity inhibitory activity against Pseudomonas aeruginosa Presenter: Hideki Maki More information: www.shionogi.com ((Comments on this story may be sent to newsdesk@closeupmedia.com))